StockGuru Blog: RxElite (SOUT) Anticipating Third Quarter Results
Stock Guru Profile News Blogs SOUT posted earnings on August 15. I am beginning to anticipate November 15 already. What we know: Sevoflurane is the most widely used inhalable anesthetic gas in the world. The price of Sevoflurane has not suffered significant erosion as it became generic. SOUT is on target with their distribution of Sevoflurane in capturing the projected 11 to 15 percent of the market in the U.S. SOUT has sales agreements in place with the hospitals who purchase Sevoflurane The Sevoflurane revenue stream should be well established this quarter and revenue should reflect that. Clearly, now is…